Work

Tigecycline as a Second-Line Agent for Legionnaires’ Disease in Severely Ill Patients

Year: 2017

Type: article

Abstract: Treatment of Legionnaires’ disease in severely ill or immunosuppressed patients presents a clinical challenge. Tigecycline (TG) achieves high concentrations intracellularly and has been shown to be effective against L. pneumophila in animal and cell models. We report our experience using TG as second-line therapy. Clinical response was seen in most patients after switching to TG alone or as a combination therapy.

Source: Open Forum Infectious Diseases

DOI: 10.1093/ofid/ofx184

Authors: Deepika Slawek, Diana Altshuler, Yanina Dubrovskaya, Eddie Louie

Institution: NYU Langone Health

Language: English

Topic: Legionella and Acanthamoeba research

Subfield: Endocrinology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,053